Cancer treatments

Nurix Therapeutics Announces Formation of DeCART Therapeutics to Advance New CAR T Therapies Using Targeted Protein Modulation

Retrieved on: 
Thursday, June 25, 2020
Medicine, Clinical medicine, Health sciences, Cancer treatments, Virotherapy, Immunotherapy, Adoptive cell transfer, Therapy, Draft:Mustang Bio, Cancer immunotherapy

SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.

Key Points: 
  • SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.
  • Dr. June will lead the DeCART founding team and also serve as the chairman of DeCARTs scientific advisory board.
  • DeCART will explore development and commercialization of CAR T cell therapies for both hematologic and solid tumors.
  • DeCART expects to combine the power of Nurixs protein modulation technologies with novel CAR T therapies to address current immunotherapy limitations and improve outcomes for patients with cancer.

Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

Retrieved on: 
Thursday, June 25, 2020
Drugs, Cancer treatments, Anthracyclines, Doxorubicin, RTT, Teratogens, Clinical medicine

This was once again confirmed by the data, as Annamycin accumulated in the lungs at nearly 6 times the level of doxorubicin.

Key Points: 
  • This was once again confirmed by the data, as Annamycin accumulated in the lungs at nearly 6 times the level of doxorubicin.
  • A greatly increased concentration of Annamycin in the lung, as compared to doxorubicin, leads to high drug efficacy in vivo in lung-localized tumor models.
  • Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition, such as WP1122.
  • Forward-looking statements in this press release include, without limitation, the ability of Annamycin to show safety and efficacy in patients with lung metastases.

Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity

Retrieved on: 
Thursday, June 25, 2020
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Medicine, Clinical medicine, Medical specialties, Immunology, Virotherapy, Cancer treatments, Oncology, Pexastimogene devacirepvec, Abscopal effect, INT230-6, Intensity Therapeutics

The paper titled, Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models, was published in IJMS as part of a Special Issue titled The Immune Landscape in Solid Tumors.

Key Points: 
  • The paper titled, Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models, was published in IJMS as part of a Special Issue titled The Immune Landscape in Solid Tumors.
  • This research demonstrates a novel, local treatment approach for cancer that minimizes systemic toxicity while stimulating adaptive immunity.
  • Several patients demonstrated tumor shrinkage, symptomatic improvement, and evidence of cancer cell death and immune cell activation on tumor biopsy.
  • Intensity Therapeutics, Inc. is a privately held, clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors

Retrieved on: 
Thursday, June 25, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Chemotherapy, Breakthrough therapy, Merck, Pembrolizumab, NT-I7, NeoImmuneTech

Dosing the first patient in this study marks a major milestone in the development of NT-I7 for the treatment of patients with advanced solid tumors, said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech.

Key Points: 
  • Dosing the first patient in this study marks a major milestone in the development of NT-I7 for the treatment of patients with advanced solid tumors, said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech.
  • We will investigate clinically NT-I7s potential to augment the already proven anti-tumor activity of pembrolizumab in CPI-responsive tumors.
  • We hope that NT-I7 in combination with KEYTRUDA can improve the lives of cancer patients with various solid tumors.
  • The goal of the Phase 1b portion of the study, which will enroll up to 18 patients, is to establish a recommended dosing regimen.

New Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo® (cemiplimab)

Retrieved on: 
Wednesday, June 24, 2020
Medicine, Medical specialties, Cancer, Immunology, Histopathology, Prostate cancer, RTT, Co-stimulation, Cancer treatments, Ipilimumab

"Adding CD28 costimulatory bispecifics to Libtayo activated T-cells against tumors more deeply and durably than Libtayo treatment alone.

Key Points: 
  • "Adding CD28 costimulatory bispecifics to Libtayo activated T-cells against tumors more deeply and durably than Libtayo treatment alone.
  • In 2020, Regeneron plans to enroll patients in clinical trials investigating three different CD28 costimulatory bispecific candidates.
  • Regeneron's first costimulatory bispecific trial, investigating the combination of PSMAxCD28 (REGN5678) and Libtayo for prostate cancer, is underway and has treated patients in several dose-escalation cohorts.
  • Another clinical trial will investigate MUC16xCD28 (REGN5668) in combination with either Libtayo or MUC16xCD3 (REGN4018) for ovarian cancer.

ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment

Retrieved on: 
Wednesday, June 24, 2020
Cancer treatments, Immune system, Checkpoint inhibitor

MOUNTAIN VIEW, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that it has identified an orally administered checkpoint inhibitor, CCX559, and plans to initiate clinical development in the first half of 2021.

Key Points: 
  • MOUNTAIN VIEW, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that it has identified an orally administered checkpoint inhibitor, CCX559, and plans to initiate clinical development in the first half of 2021.
  • Our new highly-potent, highly-specific orally administered checkpoint inhibitor furthers the Companys aim to advance novel medications that offer precise modes of action with convenient dosing and favorable safety for patients in need, said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.
  • Beyond ease of use, our orally administered small molecule approach provides flexibility in dosing schedules to more specifically fine tune checkpoint inhibition to combat tumors and avoid side effects.
  • Finally, we see potential for CCX559 as both a monotherapy or as a complement to antibody therapy regimens.

Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies

Retrieved on: 
Wednesday, June 24, 2020
Research, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Cancer treatments, Medicine, Clinical medicine, Virotherapy, Immunotherapy, Health, Cancer immunotherapy, Kite Pharma, ALPN-202, Alpine Immune Sciences, Inc.

It will enroll adults with advanced solid tumors or lymphoma refractory or resistant to standard therapy, including checkpoint inhibitors when indicated.

Key Points: 
  • It will enroll adults with advanced solid tumors or lymphoma refractory or resistant to standard therapy, including checkpoint inhibitors when indicated.
  • NEON-1 (NCT04186637), a Phase 1 study of ALPN-202 in patients with advanced malignancies, is currently enrolling.
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients lives via unique protein engineering technologies.
  • Secreted Immunomodulatory Proteins, SIP, Transmembrane Immunomodulatory Protein, TIP, Variant Ig Domain, vIgD and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 24, 2020
Health, Oncology, Medicine, Health, Clinical medicine, Cancer treatments, Oncology, Antineoplastic drugs, Medicinal chemistry, Therapy, Chimeric antigen receptor T cell, Radiation therapy, Chemotherapy, Cancer

The "CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies" report has been added to ResearchAndMarkets.com's offering.
  • For many years, the support of cancer therapy was chemotherapy, surgery and radiation therapy.
  • However, in recent times, CAR-T cell therapy has been introduced as an incredibly supportive treatment for cancer patients.
  • According to analysis, CAR-T Cell Therapy Market is expected to be USD 7.4 Billion by the end of the year 2028.

Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers

Retrieved on: 
Tuesday, June 23, 2020
Medicine, Clinical medicine, Medical specialties, Cancer treatments, Virotherapy, MediGene, Immunotherapy, T-cell receptor, Kite Pharma, Cancer immunotherapy

MDG1021, which targets the antigen HA-1, thus becomes Medigenes second proprietary T cell receptor-modified T cell (TCR-T) immunotherapy candidate to enter clinical development.

Key Points: 
  • MDG1021, which targets the antigen HA-1, thus becomes Medigenes second proprietary T cell receptor-modified T cell (TCR-T) immunotherapy candidate to enter clinical development.
  • MDG1021 is a TCR-T immunotherapy targeting a specific, immunogenic form of the antigen HA-1.
  • Phase I trial design: According to the clinical trial authorization, the trial will assess the safety and feasibility of MDG1021 immunotherapy, with secondary endpoints including preliminary efficacy.
  • Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners

Retrieved on: 
Tuesday, June 23, 2020
Medicine, Medical specialties, Clinical medicine, Immunotherapy, Immunology, Cancer treatments, Immune system, Advaxis, Virotherapy, Antigen, Adjuvant, Cell-mediated immunity

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.

Key Points: 
  • Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
  • These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins.
  • These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
  • To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.